Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Seawater fungi-derived compound screening to identify novel small molecules against dengue virus NS5 methyltransferase and NS2B/NS3 protease

Mahamudul Hasan b,* , Md. Mukthar Mia b,b,** , Shahab Uddin Munna b,1 , Md. Mowdudul Hasan Talha b,c, Kanon Das b,c

a Department of Poultry Science, Faculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, 3100, Bangladesh
b Faculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, 3100, Bangladesh
c Department of Pharmacology and Toxicology, Faculty of Veterinary, Animal and Biomedical Sciences, Sylhet Agricultural University, Sylhet, 3100, Bangladesh

ARTICLE INFO

Keywords:
Dengue virus
Marine-derived compounds
NS2B/NS3 protease
NS5 methyltransferase
Molecular docking
Target-prediction
Drug prediction

ABSTRACT

Dengue fever is a virus spread by mosquitoes that has no effective treatment or vaccination. Several dengue cases combined with the current COVID-19 pandemic, exacerbates this problem. Two proteins, NS5 methyltransferase and NS2B/NS3 primary protease complexes, are crucial for dengue viral replication and are the target sites for antiviral development. Thus, this study screened published literature and identified 162 marine fungus-derived compounds with active bioavailability. Following Lipinski’s rules and antiviral property prediction, 41 compounds were selected for docking with NS5 methyltransferase and NS2B/NS3 protease (PDB ID: 6IZZ and 2FOM) to evaluate compounds that could stop the action of dengue viral protein complexes. To find the best candidates, computational ADME, toxicity, and drug target prediction were performed to estimate the potential of the multi-targeting fungal-derived natural compounds. Analyzing the result from 41 compounds, Chevalone E (13.5 kcal/mol), Sterolic acid (10.3 kcal/mol) showed higher binding energy against dengue NS2B/NS3 protease; meanwhile, Chevalone E (−12.0 kcal/mol), Brevione K (−7.4 kcal/mol), had greater binding affinity against NS5 methyltransferase. Consequently, this study suggests that Chevalone E is an effective inhibitor of NS5 methyltransferase and NS2B/NS3 protease. Ligand-based virtual screening from DrugBank was utilized to predict biologically active small compounds against dengue virus NS2B/NS3 major protease and NS5 methyltransferase. Both licensed medications, estramustine (DB01196) and quinestrol (DB04575), were found to be similar to Chevalone E, with prediction scores of 0.818 and 0.856, respectively. In addition, cholic acid (DB02659), acitretin (DB00459), and mupirocin (DB00410) are similar to Sterolic acid, zidovudine (DB00495), imipenem (DB01598), and nadolol (DB01203) are similar to Brocazine A, and budesonide (DB01222) and colchicine (DB01394) are related to Brevione K. These findings suggest that these could be feasible dengue virus treatment options, meaning that more research is needed.

1. Introduction

Dengue virus (DENV) fever is the most common arthropod-borne viral disease in humans, affecting more than half of the world’s population [1]. DENV of the Flaviviridae family is ubiquitous and has been reported in 953,476 cases in 2021 [2], the majority of which originated in Brazil, Peru, Vietnam, France, and the Philippines. Despite the significant disease burden caused by DENV, there is no approved anti-viral therapy or vaccine that can be used to treat or prevent infection [3]. The DENV genome is formed of 11 kb single-stranded positive sense RNA that is structured as 50NCR-CprM-E-NS1-NS2A-NS2B-NS3-N-S4A-NS4B-NS5-30NCR, where NCR is the noncoding region, C is the capsid, prM is the pre-membrane, E is the envelope, and NS is the nonstructural protein. Among these proteins, envelope glycoprotein,
| Compound Name | Compound Structure | Origin | 2FOM Binding energy (kcal/mol) | 6IZZ Binding energy (kcal/mol) | Reference |
|---------------|--------------------|--------|-------------------------------|-------------------------------|-----------|
| Brocazine A   | Penicillium brocae MA-231 | –8.6   | –7.1                          | [39]                          |           |
| Chevalone E   | Aspergillus similanensis sp. | –13.5  | –12.0                         | [40]                          |           |
| Trichobotryside A | Trichobotrys effusus DFFSCS021 | –7.5   | –5.9                          | [41]                          |           |
| Engyodontiumone H | Engyodontium album DFFSCS021 | –7.1   | –5.8                          | [42]                          |           |
| Aspergilusone B | Aspergillus sydowii PSU-F154 | –7.3   | –6.3                          | [43]                          |           |
| Engyodontiumone F | Engyodontium album DFFSCS021 | –6.9   | –5.9                          | [42]                          |           |
| Stachybotrysin H | Stachybotrys chartarum | –8.3   | –6.4                          | [44]                          |           |
| Dehydrocurvularin | Penicillium sp. SF-5859 | –7.5   | –6.3                          | [45]                          |           |
| Aspergifuranone | Aspergillus sp. | –8.3   | –6.0                          | [46]                          |           |
| Penilactone A | Penicillium crustosum | –7.4   | –6.1                          | [47]                          |           |
| Sterolic acid | Penicillium sp. | –10.3  | –7.0                          | [48]                          |           |
| Brevione F | Penicillium sp. | –9.0   | –7.1                          | [49]                          |           |
| Engyodontiumone C | Engyodontium album DFFSCS021 | –7.5   | –5.9                          | [42]                          |           |
| Penipacid B | penicillium paneum | –6.6   | –5.7                          | [50]                          |           |
| Peaurantiogriseol A | Penicillium aurantiogriseum 328# | –6.3   | –5.8                          | [51]                          |           |
| Cladosin C | Cladosporium sphaerospermum 2005-01-E3 | –7.0   | –5.9                          | [52]                          |           |
| Cladosin F | Cladosporium sphaerospermum | –6.7   | –6.4                          | [52]                          |           |
| Cladosin G | Cladosporium sphaerospermum | –6.0   | –5.8                          | [52]                          |           |
| Penipacid A | penicillium paneum | –6.9   | –6.7                          | [50]                          |           |

(continued on next page)
Table 1 (continued)

| Compound Name | Compound Structure | Origin | 2FOM Binding energy (kcal/mol) | 6IZZ Binding energy (kcal/mol) | Reference |
|---------------|--------------------|--------|-------------------------------|-------------------------------|-----------|
| Brevione K    | Penicillium sp.    | −9.2   | −7.4                          | [48]                          |
| Penicimutanin A | Penicillium purpurogenum | −7.6   | −6.2                          | [53]                          |
| Integric acid | Xylaria sp.        | −6.8   | −5.3                          | [54]                          |
| Isoaspilevinone E | Aspergillus terreus Gwq-48 | −8.1   | −6.7                          | [55]                          |
| Purpurquinone B | Penicillium funiculosum No. 8974 | −8.1   | −6.4                          | [55]                          |
| Purpurquinone C | Penicillium funiculosum No. 8974 | −7.8   | −6.5                          | [56]                          |
| TAN-931       | Penicillium funiculosum No. 8974 | −7.4   | −6.7                          | [57]                          |
| Sorbicatehol A | Penicillium chrysogenum PJX-17 | −8.1   | −6.2                          | [58]                          |
| Tetrahydroaltersolanol C | Alternaria sp. ZJ-2008003 | −8.6   | −6.2                          | [59]                          |
| Acremeremophilane B | Acremonium sp. | −7.0   | −5.6                          | [60]                          |
| Chrysine B    | Penicillium chrysogenum SCSIO 41001 | −6.6   | −5.2                          | [61]                          |
| lindgomycin   | Lingomycetaceae    | −8.7   | −6.8                          | [62]                          |
| Pseudaboydin A | Pseudallescheria boydii | −6.6   | −6.5                          | [63]                          |
| Aspochalasin V | Aspergillus sp     | −7.4   | −5.7                          | [64]                          |
| Peaurantiogriseol C | Penicillium aurantiogriseum 328# | −6.4   | −5.2                          | [51]                          |
| Peaurantiogriseol D | Penicillium aurantiogriseum 328# | −6.5   | −5.2                          | [51]                          |
| Peaurantiogriseol E | Penicillium aurantiogriseum 328# | −7.0   | −6.6                          | [51]                          |
against dengue NS2b/NS3 protease and NS5 methyltransferase inhibitor. H-bond interactions of top 5 potential compounds derived from marine fungi

| Compound Name          | Compound Structure | Origin               | 2FOM Binding energy (kcal/mol) | 6IZZ Binding energy (kcal/mol) | Reference |
|-----------------------|--------------------|----------------------|-------------------------------|-------------------------------|-----------|
| Peaurantiogriseol F    | Penicillium aurantiogriseum 328# | -6.0                 | -5.0                          | [51]                          |
| Phomazine B            | Phoma sp. OUCMDZ-1847vv | -7.3                 | -6.1                          | [65]                          |
| Penikellide A          | Penicillium sp. MA-37 | -7.5                 | -5.5                          | [66]                          |
| Resveratrodehyde A     | Alternaria spp      | -7.7                 | -6.5                          | [67]                          |
| Speradine G            | Aspergillus oryzae  | -7.7                 | -6.9                          | [68]                          |

NS3 protease, NS3 helicase, NS5 methyltransferase, and NS5 RNA-dependent RNA polymerase have been proposed as potential therapeutic targets for dengue fever [4].

Antiviral research currently focuses on key viral enzymes associated with infection progression by inhibiting their biological activity directly or indirectly or by preventing the viral reproduction mechanism [5,6]. Several studies have revealed that NS2B/NS3 protease is one of the most commonly exploited targets for this purpose [7]. In addition, flavivirus proteases, such as NS2B/NS3, are required to initiate viral replication with infectivity [4]. Furthermore, DENV infection is reduced by 80% when cells are treated with peptide inhibitors of these protease enzymes [8]. Presumably, in the case of therapeutic purpose, inhibiting viral proteases is a well-known method of avoiding viral infection. HIV protease inhibitors are widely used in clinical practice to treat HIV infection [9]. Similarly, simprevir [10] and sofosbuvir [11] have recently been approved for therapeutic use against hepatitis C virus protease and have also been established as the gold standard. As a result, targeting NS2B/NS3 proteases with drugs is a widespread technique for treating DENV.

In recent years, marine fungi have been proven to be plentiful and a potential source of novel bioactive natural chemicals. Because most of these organisms exist in harsh environments, they can develop unique secondary metabolites. Metabolites are thought to represent the chemical defense response of fungi competing for substrates [12]. The range of natural chemicals produced by marine fungi suggests that some of these substances could be used in clinical trials to develop anti-infective medications.

Our study focused on using fungal bioactive compounds with potent antiviral activity against various known pathogenic viruses, such as influenza, hepatitis C virus, and herpes simplex virus, and as potential drug prototypes against DENV as a contribution to this global scientific endeavor. Thus, in this study, we used a systematic screening method to identify the top candidate for NS2B/NS3 and NS5 inhibitors of pathogenic DENV. Furthermore, computerized absorption, distribution, metabolism, excretion, and toxicity (ADMET) were analyzed to predict the potential of these multi-targeting fungal natural compounds for lead optimization and drug discovery.

### 2. Method and materials

#### 2.1. Protein dataset and binding site analysis

X-ray crystallographic structures of nonstructural (NS) methyltransferase NS5 (PDB ID: 6IZZ) and NS2B/NS3 protease (PDB ID: 2FOM) were retrieved from the Protein Data Bank (PDB). Afterwards, active drug sites of two retrieved proteins were predicted using the Computed Atlas of Surface Topography of Proteins (CASTp) server for high-resolution crystal structures and binding pockets [13].

#### 2.2. Protein and ligand preparation

Before docking investigations, each protein was opened into the
Fig. 1. Visualization of docked complex and ligand interaction with protein; (A) 2FOM-Chevalone E; (B) 2FOM-Sterolic Acid.

Fig. 2. Graphical presentation of docked complex and ligand interaction with protein; (A) 6IZZ-Chevalone E; (B) 6IZZ-Brevione K.
Discovery Studio (DS) Visualizer, and water molecules, original inhibitor, and ligand compounds were removed to upgrade the protein’s structure. The required hydrogen atoms were then inserted, followed by optimization to ensure structural stability. The final compounds were then translated to PDBQT format using the AutoDockTools-1.5.6 software.

To prepare the ligand, we examined a wide range of natural bioactive chemicals derived from marine fungi that have previously been outlined in the literature [14, 15]. Subsequently, 162 compounds were enrolled with ID numbers and chemical structures obtained from the PubChem database (Supplementary Table 1). We then refined the bioactive compounds based on molecular weights between 350 and 500 (g/mol). Next, the biological potential of the selected compounds was predicted using the prediction service PassOnline server [16], which proposes the biological activity spectra of the compounds using the SMILES files of the structures. The likelihood of becoming active (pa) parameter was set to $pa > 0.3$ for a better prediction against DENV. Finally, 41 substances were found to have antiviral properties. Then, each ligand’s SMILE file was converted to PDBQT format, loaded into the AutoDockTools-1.5.6 software, and set up using the prepared ligand preparation tool for docking analysis.

2.3. Active site prediction and molecular docking

For molecular docking experiments, we used the default procedure in AutoDock tools 1.5.6 [17]. A grid box was created around the active site of DENV virus NS5 methyltransferase and NS2B/NS3 protease, as well as 2FOM and 6IZZ, with the help of a DS Visualizer. In addition, we set the grid box at $40 \times 40 \times 40$ points in the xyz-dimension, which equaled a grid box spacing of 0.3753, and fixed the coordinates of the x, y, and z centers as 0.387667, 6.969833, and 12.141667 for NS2B/NS3; meanwhile, 15.658143, 19.544214, and 38.773643 for NS5. We employed the Lamarckian genetic algorithm with default parameters for docking simulations, which included 10 genetic algorithm runs. Using the DS Visualizer, we further investigated the molecule with the highest energy ranking for protein-ligand interactions.

2.4. Drug profile analysis of top compounds

Absorption, distribution, metabolism, and excretion (ADME) are the four key criteria that determine drug levels and kinetics of drug exposure in an organism’s tissues. These characteristics play a major role in the pharmacological activity and performance [18]. The SwissADME server was used to evaluate the ADME properties of the top five metabolites [19]. The blood-brain barrier (BBB) in the examined substances was calculated using the BOILED-Egg model [20].

2.5. Toxicity, carcinogenicity, and mutagenicity prediction

To predict toxicity, mutagenicity, and carcinogenic effects, canonical
Informatics in Medicine Unlocked 30 (2022) 100932

Informatics in Medicine Unlocked 30 (2022) 100932

SMILES of the selected compounds that displayed predicted antiviral activity were uploaded to the pkCSM server [21] and proTox-ll databases [22]. The toxicity was predicted using the toxicity mode in the pkCSM server, and the ProTox-ll server was used to assess carcinogenicity and mutagenicity. By combining the molecular similarity, fragment tendency, and fragment similarity approaches, this popular server effectively predicts numerous toxicity outcomes [23]. Based on the analysis of 2-dimensional (2D) similarity to substances with a known median lethal dose, the server also projected the oral toxicity (LD50). The list used for the prediction contained almost 38,000 different chemicals with known oral LD50 values in mice [24].

2.6. Prediction of drug target and available drug molecules from DrugBank

The SwissTargetPrediction server was used to determine the potential macromolecular targets of the therapeutic candidates [25]. Based on a combination of 2D and 3D similarities with a library of 370,000 known bioactive chemicals on approximately 3000 proteins, the server makes predictions. Analyzing the homology screening of anticipated top drug candidates, the SwissSimilarity web tools were utilized to find possible therapeutic compounds against DENV virus NS5 methyltransferase and NS2B/NS3 protease. Using diverse methodologies, such as FP2 fingerprints, electrophores, and spectrophores [26], the server allows ligand-based virtual screening of several libraries of small compounds to locate authorized, investigational, or commercially accessible medications from DrugBank.

2.7. Molecular dynamics simulations

The iMOD server was used to analyze the structural dynamics of the best protein-ligand combination and to evaluate the stability of the structure by applying deformability analysis, which included the computation of the eigenvalues of the complexes [27,28]. This is a web server that can be customized and can generate complex deformability, variance, B-factor, covariance map data, and elastic network data. The deformability of a complex or protein is determined by its ability to deform at each amino acid residue [29]. The eigenvalue is equal to the energy difference required to bend a particular structure; therefore, the smaller the eigenvalue, the easier it is to deform the complex. The eigenvalue also represents the stiffness of the protein complex [30].

3. Results and discussion

3.1. Analysis of drug surface hotspot and ligand binding pocket

The drug surface hotspots of the selected NS5 methyltransferase and NS2B/NS3 protease with the ligand were investigated based on the structural conformation of the docked complexes. The ligand-binding patterns as well as the locations of the interacting residues are shown in Table 2. The positions of amino acids 127–161 were found to be crucial for NS2B/NS3 binding interactions (2FOM). Contrarily, the
amino acids from positions 806 to 840 showed the interactions with NS5 (6IZZ) protease. Additionally, CASTp was used to confirm the binding site residues of the two target proteins.

### 3.2. The binding affinities of the ligands into NS2B/NS3 and NS5 active site

The results of docking details were recovered after docking all the ligands with NS2B/NS3 protease and NS5 methyltransferase target in Table 1. The molecules that had the lowest binding energy of the docking score were considered the best molecules and had a higher binding affinity with the target receptors [31]. Moreover, the lower the stabilization energy of ligand binding to the receptor, the greater the potential of action was. To limit the probability of false-positive results, the ideal binding energy of marine fungal-derived compounds was compared with that of the approved clinical chemical treatments, and the binding energy in the screening criterion was amended to a negative value > -5 kcal/mol [32] to reduce the risk of false-positive results. The four best components are presented in Table 2, and the docking scores of all the compounds are listed in Table 1. Out of 41 compounds, including Chevalone E (-13.5 kcal/mol), Sterolic acid (-10.3 kcal/mol), Brevione K (-9.2 kcal/mol), Brevione F (-9.0 kcal/mol), lindgomycin (-8.7 kcal/mol), Tetrahydroaltersolanol C (-8.6 kcal/mol) showed higher binding energy against dengue NS2B/NS3 protease; meanwhile, Chevalone E (-12), Brevione K (-7.4 kcal/mol), Brocazine A (-7.1 kcal/mol), Brevione F (-7.1 kcal/mol), Sterolic acid (-7.0 kcal/mol), and Speradine G (-6.9 kcal/mol) had greater binding affinity against NS methyltransferase of dengue virus. Contrastingly, Peaurantiogriseols compounds, Penikellide A, Resveratrodehyde A, Remeremophilane B, and Engyodontiumone H showed the lowest binding affinity against viral NS5 methyltransferase but had moderate binding affinity against viral NS2B/NS3 protease.

In the previous study, the in-silico highest binding affinities of Artesunic acid and Homoegonol against the NS5 methyl transferase reported as -7.2 and -7.1 kcal/mol [33], which refers the slightly higher binding affinity energy of our selected compounds (Chevalone E, Brevione K, Brocazine A, and Brevione F). In another study were revealed that apigenin and luteolin phytocompounds showed the highest binding affinity (-7.7 kcal/mol) against dengue NS2B/NS3 protease [34] that was dissimilar from our results we found more binding affinity -13.5, -10.5, -9.2 and -9.0 kcal/mol for Chevalone E, Sterolic acid, Brevione K, Brevione F, respectively. In addition, [35] reported a lower binding affinity for phytocompounds based on the binding affinity of the above-listed compounds. The ligand-receptor interactions are shown in Figs. 1 and 2.

### 3.3. Hydrogen bond analysis

The complex interactions between NS2B/NS3 and NS5 with inhibitory ligands were visualized using a DS Visualizer, and a hydrogen bond analysis was also performed. In the Table 2, the numbers of hydrogen bonds and residues implicated in hydrogen bond interactions were summarized. Chevalone E, Sterolic acid, Brocazine K, Brevione F, and lindgomycin are possible NS2B/NS3 inhibitor candidates with drug-like
properties and no toxicity, carcinogenicity, or mutagenicity. At the residues of SER127, LEU128, GLY153, and HIS51, Sterolic acid forms four hydrogen bonds, whereas only the ARG54 residue was formed in the case of Brocazine K. Moreover, Brevione F and Lindgomycin (GLY151: 2.37) showed that they could also be used as NS2B/NS3 inhibitors. Contrarily, at the residues TYR838 and ILE717, Brocazine A formed hydrogen bonds with viral NS5 methyltransferase. In addition, Sterolic acid had three hydrogen bonds interacting with the active site of NS5 methyltransferase at residues ALA757, TRP803, and GLU509. Interestingly, despite the fact that Brevione K had a higher binding affinity, this combination was unable to form hydrogen bonds. Therefore, Brocazine A, with two hydrogen bonds, was found to be the best inhibitor of NS5 methyltransferase. The common interactions of the examined compounds, when compared to the original inhibitor, suggest that marine-derived fungal compounds Chevalone E, Sterolic acid, Brevione F, and Brocazine A (Fig. 3) could be potential inhibitors of NS2B/NS3 protease and NS5 methyltransferase.

### Table 4
Toxicity, mutagenicity and carcinogenicity prediction of selected bioactive compounds.

| Bioactive compounds name | Chevalone E | Sterolic Acid | Brevione F | Brocazine A |
|--------------------------|-------------|---------------|------------|-------------|
| AMES toxicity            | No          | No            | No         | No          |
| hERG I inhibitor         | No          | No            | No         | No          |
| hERGII inhibitor         | No          | No            | No         | No          |
| Oral Rat Acute Toxicity (LD50) | 2.122  | 2.541         | 2.664      | 3.486       |
| Oral Rat Chronic Toxicity (LOAEL) | 0.891  | 1.437         | 1.477      | 1.983       |
| Hepatotoxicity           | No          | No            | No         | No          |
| Immunosensitisation      | No          | No            | No         | No          |
| Minnow toxicity          | 1.015       | 0.973         | 0.25       | 5.734       |
| Mutagenicity             | Inactive (0.82) | Inactive (0.80) | Inactive (0.84) | Inactive (0.69) |
| Carcinogenicity          | Inactive (0.67) | Inactive (0.54) | Inactive (0.53) | Inactive (0.69) |
| Immunotoxicity           | Active (0.90)  | Active (0.97)  | Active (0.99)  | Active (0.64)  |
| Aryl hydrocarbon Receptor (AhR) | Inactive (0.96) | Inactive (0.92) | Inactive (0.92) | Inactive (0.92) |
| Androgen Receptor (AR)   | Inactive (0.88) | Inactive (0.60) | Inactive (0.63) | Inactive (0.94) |
| Androgen Receptor Ligand Binding Domain (AR-LBD) | Inactive (0.86) | Inactive (0.53) | Inactive (0.52) | Inactive (0.94) |
| Aromatase                | Inactive (0.76) | Inactive (0.58) | Inactive (0.58) | Inactive (0.90) |
| Estrogen Receptor Alpha (ER) | Inactive (0.72) | Inactive (0.65) | Inactive (0.65) | Inactive (0.88) |
| Estrogen Receptor Ligand Binding Domain (ER-LBD) | Inactive (0.90) | Inactive (0.90) | Inactive (0.89) | Inactive (0.92) |
| Peroxisome Proliferator Activated Receptor Gamma (PPAR-Gamma) | Inactive (0.85) | Inactive (0.85) | Inactive (0.84) | Inactive (0.89) |
| Nuclear factor (erythroid-derived 2)-like 2/antioxidant responsive element (nrf2/ARE) | Inactive (0.83) | Inactive (0.93) | Inactive (0.90) | Inactive (0.87) |
| Heat shock factor response element (HSE) | Inactive (0.83) | Inactive (0.93) | Inactive (0.90) | Inactive (0.87) |
| Mitochondrial Membrane Potential (MMP) | Inactive (0.56) | Inactive (0.62) | Inactive (0.52) | Inactive (0.83) |
| Phosphoprotein (Tumor Suppressor) p53 | Inactive (0.72) | Inactive (0.58) | Inactive (0.57) | Inactive (0.84) |
| ATPase family AAA domain-containing protein 5 (ATAD5) | Inactive (0.95) | Inactive (0.91) | Inactive (0.92) | Inactive (0.92) |

Fig. 5. Prediction of drug targets for (A) Chevalone E (B) Sterolic Acid, and (C) Brevione K.
A. Predicted drug targets for Chevalone E, Sterolic acid, Brevione K, and Brocazine A.

Table 5

| Target | Common name | UniProtKB ID | Target Class | Probability |
|--------|-------------|--------------|--------------|-------------|
| Sterolic Acid | ATP2A1 | O14983 | Hydrolase | 0.1106122 |
| Acid | PCSK7 | Q16549 | Protease | 0.1106122 |
| Isoleucyl-tRNA synthetase | IARS | P41252 | Enzyme | 0.1106122 |
| Proto-oxogenec e-JUN | JUN | P05412 | Transcription factor | 0.1106122 |
| Protein kinase C alpha | PRKCA | P17225 | Kinase | 0.1106122 |
| Cyclooxygenase-2 | PTGS2 | P35354 | Oxidoreductase | 0.1106122 |
| Glutathione S-transferase Mu 1 | GSTM1 | P90488 | Enzyme | 0.1106122 |
| Protein kinase C epsilon | PRKCE | Q02156 | Kinase | 0.1106122 |
| Cytochrome P450 19A1 | CYP19A1 | P11511 | Cytochrome P450 | 0.1106122 |
| LanC-like protein 2 | LANC2 | Q9N8S6 | Unclassified protein | 0.1106122 |
| Proteinase-activated receptor 2 | F2RL1 | P55085 | Family A G protein-coupled receptor | 0.1106122 |
| Voltage-gated potassium channel subunit Kv1.3 | KCNA3 | P22001 | Voltage-gated ion channel | 0.1106122 |
| Transient receptor potential cation channel subfamily V member 4 (by homology) | TRPV4 | Q9HIA0 | Voltage-gated ion channel | 0.1106122 |
| Integrin alpha-4/beta-1 | ITGB1 ITGA4 | P05556 | Membrane receptor | 0.1106122 |
| Zinc finger protein GLI1 | GLI1 | P08151 | Transcription factor | 0.1106122 |
| Brevione K Voltage-gated potassium channel subunit Kv1.5 | KCNA5 | P22460 | Voltage-gated ion channel | 0.106542926 |
| Protein farnesyltransferase | FNTA | P49354 | Enzyme | 0.106542926 |
| 11-beta-hydroxysteroid dehydrogenase 1 | HSD11B1 | P28485 | Enzyme | 0.106542926 |
| C-C chemokine receptor type 5 | CCR5 | P51681 | Family A G protein-coupled receptor | 0.106542926 |
| Steroid S-alpha-reductase 1 | SRD5A1 | P18405 | Oxidoreductase | 0.106542926 |
| Steroid S-alpha-reductase 2 | SRD5A2 | P31213 | Oxidoreductase | 0.106542926 |
| Cytochrome P450 19A1 | CYP19A1 | P11511 | Cytochrome P450 | 0.106542926 |
| Phosphodiesterase 10A (by homology) | PDE10A | Q9Y233 | Phosphodiesterase | 0.106542926 |
| Telomerase reverse transcriptase | TERT | P14746 | Enzyme | 0.106542926 |
| Orexin receptor 2 | HCNR2 | O43614 | Family A G protein-coupled receptor | 0.106542926 |
| Orexin receptor 1 | HCNR1 | O43613 | Family A G protein-coupled receptor | 0.106542926 |
| Glucocorticoid receptor | NR3C1 | P04150 | Nuclear receptor | 0.106542926 |
| Kinesin-like protein 1 | KIF11 | P52732 | Other cytosolic protein | 0.106542926 |
| PI3-kinase p110-alpha subunit | PIK3CA | P42336 | Enzyme | 0.106542926 |
| MAP kinase g38 alpha | MAPK14 | P14746 | Enzyme | 0.106542926 |
| Chevalone E 11-beta-hydroxysteroid dehydrogenase 1 | HSD11B1 | P28485 | Enzyme | 0.106542926 |
| Cytochrome P450 17A1 | CYP17A1 | P14746 | Enzyme | 0.106542926 |
| Serotonin 2b (5-HT2b) receptor | HTR2B | P41595 | Family A G protein-coupled receptor | 0.106542926 |
| Androgen Receptor (by homology) | AR | P10275 | Nuclear receptor | 0.106542926 |
| Adrenergic receptor alpha-2 | ADRB2 | P18825 | Family A G protein-coupled receptor | 0.106542926 |
| Glucocorticoid receptor | NR3C1 | P04150 | Nuclear receptor | 0.106542926 |
| Estrogen receptor alpha | ESR1 | P03792 | Nuclear receptor | 0.106542926 |
| Serotonin transporter | SLC6A4 | P31645 | Electrochemical transporter | 0.106542926 |
| Testis-specific androgen-binding protein | S192 | P02479 | Secreted protein | 0.106542926 |
| Cytochrome P450 19A1 | CYP19A1 | P11511 | Cytochrome P450 | 0.106542926 |
| Phosphodiesterase 10A | PDE10A | Q9Y233 | Phosphodiesterase | 0.106542926 |
| Voltage-gated potassium channel subunit Kv1.3 | KCNA3 | P22001 | Voltage-gated ion channel | 0.106542926 |
| Estrogen receptor beta | ESR2 | Q92731 | Nuclear receptor | 0.106542926 |
| Peroxisome proliferator-activated receptor gamma | PPARG | P37231 | Nuclear receptor | 0.106542926 |
| Tyrosine-protein kinase FYN | FYN | P06241 | Kinase | 0.106542926 |

3.4. In silico evaluation of drug likeness and ADME

The ADME approach was used to analyze the drug-likeness of the top four compounds found in the marine-derived fungi. Forecasts were made using the SwissADME database. The likeness of the drug was demonstrated by five rules established by Lipinski. The molecular weight (MW) should be between 350 and 500 (g/mol), the number of hydrogen bond acceptors should be between (5), the number of hydrogen bond donors should be between (5), and the Log Po/w should be between 5 and 10 [36], with no more than one violation allowed. Chevalone E, Brevione K, and Sterolic acid had higher gastrointestinal absorption than Brocazine A. Furthermore, the BOILED-Egg model was used to compute BBB penetration, which demonstrated that none of the top medication candidates tested had BBB permeation. Each compound was water soluble to varying degrees, with Sterolic acid having the...
Fig. 6. Molecular dynamics simulation analysis, deformability: (A) Chevalone E – NS2B/NS3 protease, (B) Chevalone E – NS5 methyltransferase; Bfactor: (C) Chevalone E – NS2B/NS3 protease, (D) Chevalone E – NS5 methyltransferase; and stability (eigen value): (E) Chevalone E – NS2B/NS3 protease, (F) Chevalone E – NS5 methyltransferase.

Fig. 7. Molecular dynamics simulation analysis: co-variance map: (A) Chevalone E – NS2B/NS3 protease; (B) Chevalone E – NS5 methyltransferase; and elastic network: (C) Chevalone E – NS2B/NS3 protease and (D) Chevalone E – NS5 methyltransferase.
highest solubility (Table 3). Therefore, these molecules can be used to mimic the effects of drugs (Fig. 4).

3.5. Toxicity, carcinogenicity and mutagenicity prediction

Acute toxicity, hepatotoxicity, carcinogenicity, mutagenicity, immunotoxicity, and toxicity targets were explored as the toxicity endpoints. The results revealed that Chevalone E and Brevione K fell in the category of toxicity class 4, while Sterolic acid and Brocazine A showed toxicity levels of 1 and 3, respectively (the lower the class, the higher the toxicity). The estimated LD50 of Chevalone E, Sterolic acid, Brevione K, and Brocazine A were 1600, 34, 1255, and 75 mg/kg, respectively. The toxicity characteristics in (Table 4) depict the level of confidence in the positive toxicity results compared to the class average. No unfavorable effects such as tumorigenicity, mutagenicity, irritation, or reproductive consequences were observed for any of the compounds.

3.6. Prediction of drug targets, available drug molecules from DrugBank and molecular dynamics simulation

Molecular target investigations are required to uncover the phenotypical side effects or possible cross-reaction caused by their actions. This is the first step in determining the viability of using the drug in future in vitro and in vivo experiments [37]. As a result, Fig. 5 shows the top 25 findings generated by SwissTargetPrediction [38] for Chevalone E (NS2B/NS3 and NS5 inhibitor), Sterolic acid (NS2B/NS3 inhibitor), and Brevione K (NS2B/NS3 and NS5 inhibitor). The target sites that the chemical could bind to were largely protease and enzyme (13.3%) for Sterolic acid, nuclear receptor (33.3%) for Chevalone E, and enzyme (26%) for Brevione K (Table 5).

Ligand-based virtual screening was used to predict biologically active small molecules against NS2B/NS3 protease and NS5 methyltransferase of dengue from DrugBank. Estramustine (DB01196) and Quinestrol (DB00459), both licensed medications, were similar to Chevalone E, with prediction scores of 0.818 and 0.856, respectively. Furthermore, the results revealed that cholic acid (DB02659), actretin (DB00459), and mupirocin (DB00410) are similar to Sterolic acid; zidovudine (DB00495), imipenem (DB01598), and nadolol (DB01203) are similar to Brocazine A; and Budesonide (DB01222) and Colchicine (DB01394) are similar to Brevione K (Table 6). These findings indicate that these could be viable therapeutic candidates for DENV infection, implying that further research is needed. In addition, based on molecular dynamics modeling, the best complexes for NS5 methyltransferase-Chevalone E and NS2B/NS3 protease-Chevalone E showed satisfactory eigenvalues with structural stability. The maximal eigenvalue of the top 25 findings generated by SwissTargetPrediction [38] for Chevalone E (NS2B/NS3 and NS5 inhibitor), Sterolic acid (NS2B/NS3 inhibitor), and Brocazine A; and Budesonide (DB01222) and Colchicine (DB01394) are similar to Brevione K (Table 6). These findings indicate that these could be viable therapeutic candidates for DENV infection, implying that further research is needed. In addition, based on molecular dynamics modeling, the best complexes for NS5 methyltransferase-Chevalone E and NS2B/NS3 protease-Chevalone E showed satisfactory eigenvalues with structural stability. The maximal eigenvalue of the top 25 findings generated by SwissTargetPrediction [38] for Chevalone E (NS2B/NS3 and NS5 inhibitor), Sterolic acid (NS2B/NS3 inhibitor), and Brocazine A; and Budesonide (DB01222) and Colchicine (DB01394) are similar to Brevione K (Table 6).

4. Conclusions

Currently, there are no specific treatments for dengue. Although few studies have been conducted to develop dengue vaccines, this process has a great deal to be accomplished. As a result, scientists are currently looking for inhibitors to block DENV’s key methyltransferase and protease, NS5 and NS2B/NS3, which are involved in viral replication, as targets for next-generation therapeutic development. On the contrary, marine fungi have proven to be a rich and promising source of novel bioactive natural compounds and may be able to suppress viral NS5 and NS2B/NS3 activities. In this study, the primary viral protease was docked against marine-derived chemicals. In addition, drug-like characteristics, toxicity, carcinogenicity, and mutagenicity were predicted using in silico ADMET analysis. Analyzing the results, our study suggests that Chevalone E, Sterolic acid, Brevione K, and Brocazine A found in marine-derived fungi are the best NS5 and NS2B/NS3 inhibitors. The predicted drug based on the ligand estramustine, cholic acid, actretin, colchicine, and zidovudine could be exploited and developed as an alternative or complementary therapy for the treatment of dengue virus.

Funding information

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT author statement

Md. Mukhtar Mia & Mahamudul Hasan: Conceptualization, Methodology, Software. Mahamudul Hasan, Shahab Uddin Munna, Md Mowdudul Hasan Talha and Kanon das: Writing- Original draft preparation. Md. Mukhtar Mia & Mahamudul Hasan: Visualization, Investigation. Md. Mukhtar Mia: Supervision. Validation. Md. Mukhtar Mia, Mahamudul Hasan, Shahab Uddin Munna, Md Mowdudul Hasan Talha: Writing- Reviewing and Editing.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Authors would like to acknowledge all the members of the Faculty of Veterinary, Animal and Biomedical Sciences, (SAU) for the methodological support of the project.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jimu.2022.100932.

References

[1] Dighe SN, Dua K, Chellappan DK, Katacic PL, Collet TA, others. Recent update on anti-dengue drug discovery. Eur J Med Chem 2019;176:431–55. https://doi.org/10.1016/j.ejmech.2019.05.010.
[2] Cdc EC for DP and C. Dengue worldwide overview. https://www.ecdc.europa.eu/en/dengue-monthly, [Accessed 10 March 2022].
[3] Troost B, Smit JM. Recent advances in antiviral drug development towards dengue virus. Curr Opin Virol 2020;43:9–21. https://doi.org/10.1016/j.co vireo.2020.07.009.
[4] Cabarcas-Montalvo M, Maldonado-Rojas W, Montes-Grajales D, Bertel-Segovia A, Wagner-Doebler I, Szajer H, et al. Discovery of antiviral molecules for dengue: in silico search and biological evaluation. Eur J Med Chem 2016;110:87–97. https://doi.org/10.1016/j.ejmech.2015.12.030.
[5] Lou Z, Sun Y, Rao Z. Current progress in antiviral strategies. Trends Pharmacol Sci 2014;35:86–102. https://doi.org/10.1016/j.tips.2013.11.006.
[6] Gu W, Ip DT-M, Liu S, Chan JH, Wang Y, Zhang X, et al. 1-Bis-(5-(naphthalen-1-yl) thioneph-2-yl) naphthalene, a small molecule, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular Lens epithelium-derived growth factor. Chem Biol Interact 2014;212:21–7. https://doi.org/10.1016/j.cbii.2014.01.011.
[7] Yang C-C, Hu H-S, Wu R-H, Wu S-H, Lee S-J, Jiaang W-T, et al. A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease. Antimicrob Agents Chemother 2014;58:110–9. https://doi.org/10.1128/AAC.01281-15.
[8] Rothan HA, Han HC, Ramasamy TS, Othman S, Abd Rahman N, Yusof R. Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. BMC Infect Dis 2012;12:1–9. https://doi.org/10.1186/1471-2334-12-314.
[9] Hughes PJ, Creton-Scott E, Teague A, Wessel TM. Protease inhibitors for patients with HIV-1 infection: a comparative overview. Pharmacol Ther 2011;26:332.
[10] Forna X, Lazitve E, Zsuzsman S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669–79. https://doi.org/10.1053/j.gastro.2014.02.053.
[11] Keating GM, Vaidya A. Sofosbuvir: first global approval. Drugs 2014;74:273–82. https://doi.org/10.1007/s40265-014-0179-7.
[12] Yashubara-Bell J, Lui Y. Marine compounds and their antiviral activities. Antivir Res 2010;86:231–40. https://doi.org/10.1016/j.antiviral.2010.03.009.
[62] Wu B, Wiese J, Labes A, Kramer A, Schmaljohann R, Imhoff JF. Lindgomycin, an unusual antibiotic polyketide from a marine fungus of the Lindgomycetaceae. Mar Drugs 2015;13:4617–32. https://doi.org/10.3390/md13084617.

[63] Lan W-J, Liu W, Liang W-L, Xu Z, Xu J, et al. Pseudaboydins A and B: novel isobenzofuranone derivatives from marine fungus Pseudallescheria boydii associated with starfish Acanthaster planci. Mar Drugs 2014;12:4188–99. https://doi.org/10.3390/md12074188.

[64] Liu Y, Zhao S, Ding W, Wang P, Yang X, Xu J. Methylthio-aspochalasins from a marine-derived fungus Aspergillus sp. Mar Drugs 2014;12:5124–31. https://doi.org/10.3390/md1205124.

[65] Kong F, Wang Y, Liu P, Dong T, Zhu W. Thiodiketopiperazines from the marine-derived fungus Phoma sp. OUCMDZ-1847. J Nat Prod 2014;77:132–7. https://doi.org/10.1021/jp500839d.

[66] Luo H, Li X-M, Li C-S, Wang B-G. Diphenyl ether and benzophenone derivatives from the marine mangrove-derived fungus Penicillium sp. MA-37. Phytochem Lett 2014;9:22–5. https://doi.org/10.1016/j.phytol.2014.03.012.

[67] Wang J, Cox DG, Ding W, Huang G, Lin Y, Li C. Three new resveratrol derivatives from the mangrove endophytic fungus Alternaria sp. Mar Drugs 2014;12:2840–50. https://doi.org/10.3390/md12052840.

[68] Hu X, Xia Q-W, Zhao Y-Y, Zheng Q-H, Liu Q-Y, Chen L, et al. Speradines F–H, three new oxindole alkaloids from the marine-derived fungus Aspergillus oryzae. Chem Pharm Bull 2014;62:4-00312. https://doi.org/10.1248/cpb.c14-00312.